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ABSTRACT
The CRISPR-Cas9 system has revolutionized genome engineering, allowing precise modiﬁcation of DNA in
various organisms. The most popular method for conducting CRISPR-based functional screens involves the
use of pooled lentiviral libraries in selection screens coupled with next-generation sequencing. Screens
employing genome-scale pooled small guide RNA (sgRNA) libraries are demanding, particularly when
complex assays are used. Furthermore, pooled libraries are not suitable for microscopy-based high-
content screens or for systematic interrogation of protein function. To overcome these limitations and
exploit CRISPR-based technologies to comprehensively investigate epigenetic mechanisms, we have
generated a focused sgRNA library targeting 450 epigenetic regulators with multiple sgRNAs in human
cells. The lentiviral library is available both in an arrayed and pooled format and allows temporally-
controlled induction of gene knock-out. Characterization of the library showed high editing activity of
most sgRNAs and efﬁcient knock-out at the protein level in polyclonal populations. The sgRNA library can
be used for both selection and high-content screens, as well as for targeted investigation of selected
proteins without requiring isolation of knock-out clones. Using a variety of functional assays we show that
the library is suitable for both in vitro and in vivo applications, representing a unique resource to study









Clustered regularly interspaced short palindromic repeats
(CRISPR) in combination with CRISPR-associated proteins
(Cas) provide a defense mechanism to bacteria and archaea
against foreign genetic material [1,2]. Because of its ability to
cleave DNA in speciﬁc regions, the CRISPR/Cas9 system has
recently been adapted to allow precise genome editing in vari-
ous organisms [3]. Expression of the Cas9 nuclease into a cell,
in conjunction with a synthetic small guide RNA (sgRNA),
allows targeting of the Cas9/sgRNA complex to a desired geno-
mic location and induction of double-strand breaks (DSBs)
that will be repaired by either non-homologous end-joining
(NHEJ) or homologous recombination (HR) [3,4]. Depending
on the experimental setting, the CRISPR/Cas9 system can be
used to induce gene knockout (KO) [5,6], introduce or correct
speciﬁc mutations in the genome [6–8], delete regulatory
regions [9], induce translocations [10], activate or repress gene
expression [11], pull-down speciﬁc genomic regions [12], or
visualize genomic loci [13].
A major application of the CRISPR/Cas9 system is per-
forming loss-of-function screens [3], [14]. NHEJ is the pre-
dominant repair pathway in mammalian cells and often
results in the formation of insertions or deletions (in/dels)
that disrupt gene function [15]. The ability to induce com-
plete loss of the target protein through gene knockout
offers several advantages compared to RNA interference-
based methods, including improved signal-to-noise ratio
and lower off-target effects [16],[17]. The CRISPR/Cas9
system has recently been used in selection screens to iden-
tify, among others, essential genes in mammalian cells [5],
[18], synthetic lethal genes,[19] HIV host dependency fac-
tors [20], genetic vulnerabilities in cancer [21],[22], and
regulatory networks in immune cells [23]. These screens
utilized pooled sgRNA libraries generated by cloning chip-
synthesized oligonucleotides covering the entire human or
mouse transcriptome into lentiviral vectors. Upon trans-
duction of the libraries into cells, sgRNAs inducing a
selectable phenotype were identiﬁed by next-generation
sequencing.
Pooled libraries are particularly suitable for positive selec-
tion screens, in which KO of important genes confers a strong
selective advantage and enrichment of the corresponding
sgRNAs. The CRISPR/Cas9 system also enables drop-out
screens and has been used to identify dependencies of cancer
cells [5],[18]. Due to the high rate of false positives in selection
screens, only substantial phenotypic changes induced by gene
KO can be detected, and subtler phenotypes are typically
missed. Systematic interrogation of all proteins involved in a
pathway or a process is therefore not possible. Furthermore,
pooled libraries are not suitable when complex or microscopy-
based readouts are used, for which libraries containing individ-
ual sgRNAs in an arrayed format are required. Although
CONTACT Paola Scafﬁdi paola.scafﬁdi@crick.ac.uk
Supplemental data for this article can be accessed at htttp://dx.doi.org/10.1080/15592294.2017.1395121.
© 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided the original work is properly cited.
EPIGENETICS, 2017
VOL. 12, NO. 12, 1065–1075
https://doi.org/10.1080/15592294.2017.1395121
whole-genome arrayed libraries that allow comprehensive
interrogation of gene function have been generated [24], they
require large amounts of reagents, automated equipment and
dedicated facilities. Moreover, many screens do not require
examination of the whole genome and focused libraries target-
ing classes of related proteins may provide a more suitable tool
to effectively address speciﬁc questions.
Epigenetic mechanisms play a critical role in development,
tissue homeostasis and contribute to various diseases, including
cancer, syndromes associated with neurological defects and
heart disease [25],[26]. Owing to their inherent reversibility,
epigenetic mechanisms represent promising therapeutic targets
and identiﬁcation of novel epigenetic regulators involved in dis-
ease may open new avenues for therapeutic intervention. Here,
we report the generation and characterization of an sgRNA
library targeting most known human epigenetic regulators with
multiple guides, suitable for both selection and high-content




Epigenetic regulators to be targeted were selected based on
Gene Ontology, including proteins involved in chromosome
organization, chromatin modiﬁcation, and regulation of
DNA methylation. Additional proteins were included based
on overall similarity with known epigenetic regulators or the
presence of protein domains predicted to bind to or modify
chromatin (e.g., chromodomain, bromodomain or SET
domain). Selected proteins involved in DNA damage
response and repair were also included in the list of targets.
All together, 450 genes were selected for targeting (Fig. 1A,
Supplementary Table 1).
For each gene, we designed 5 different sgRNAs (sgRNA
groups 1–5) using the CRISPR MIT Designer (crispr.mit.edu)
[27]. Where possible, sgRNAs were designed to target the ﬁrst
translated exon common to all RefSeq isoforms of each gene
(Fig. 1B and Supplementary Fig. 1A). To minimize off-target
effects, we preferentially selected sgRNAs with scores of at least
70, a value that typically characterizes highly speciﬁc sgRNAs
[27] (Fig. 1C). When targeting of a shared exon with a speciﬁc
sgRNA was not possible, the most 5’ exon of the primary
RefSeq variant was used. (Supplementary Fig. 1A). As an addi-
tional criterion, whenever possible, we ensured that targets had
at least 3 non-overlapping guides. Based on the above strategy,
the designed set of guides comprised 98% of sgRNAs with score
70 (Fig. 1C), 74% of sgRNAs targeting the N-terminus part of
the corresponding proteins (% of remaining peptide 25)
(Fig. 1D, blue boxes), and 90% of sgRNAs with optimal GC
content (35-70%) [28] (Fig. 1E, blue histogram). Furthermore,
analysis of the designed sgRNAs using an algorithm that pre-
dicts guide efﬁcacy [29] showed that 82% of the sgRNAs had
an Azimuth RS2 score 0.4 (range: 0.04-0.81), indicating high
predicted activity (Fig. 1F, blue boxes). Similar results were
obtained analyzing the sgRNA sequences using RNA Scorer
2.0, a different predictive algorithm[30] (Supplementary
Fig. 2A,B). Thus, the designed sgRNA groups 1–5 are predicted
to generate short truncated proteins, with minimal off-target
effects and high efﬁcacy.
For each gene in the library, 2 additional guides (sgRNA
groups 6–7) were selected from the whole-genome CRISPR
library constructed by Wang et al., [18] which comprises
sgRNAs primarily designed based on predicted efﬁcacy. Unlike
sgRNAs groups 1–5, the sgRNA groups 6–7 do not target pref-
erentially 5’ exons and showed a more uniform distribution
along genes (Fig. 1D, yellow boxes), but had comparable GC
content and higher Azimuth RS2 score (Fig. 1E-F). The com-
bined sgRNA groups resulted in a library of 3150 unique
sgRNA sequences with 7 sgRNAs per target gene (Supplemen-
tary Table 2).
To achieve efﬁcient in/del generation, we chose a selectable
lentiviral vector for delivery of sgRNAs into cells. pLen-
ti_BSD_sgRNA, generated by substituting the EGFP coding
region of the pLenti plasmid [31] with a cDNA (BSD) encoding
resistance to the antibiotic blasticidin, allows efﬁcient expres-
sion of sgRNAs under a human U6 promoter (Fig. 2A). To be
amenable for large scale cloning, the vector of choice should
allow fast and efﬁcient cloning of sgRNAs, and eliminate any
background by empty vector. pLenti_BSD_sgRNA contains
two BsmBI restriction sites, which allow efﬁcient plasmid diges-
tion and insert ligation in a single reaction by Golden Gate
cloning. Moreover, the vector contains a ccdB suicide gene,
which is replaced by the sgRNA upon cloning (Fig. 2A), pre-
venting propagation of the empty vector and allowing highly
efﬁcient selection of bacteria transformed by the correct plas-
mid without needing to plate them on solid medium.
Library production
For each sgRNA, individual forward and reverse oligos tagged
with appropriate 5’ overhangs compatible with the BsmBI-
based ligation were synthesized in 96-well format (2 £ 33
plates). Annealed oligos were cloned into pLenti_BSD_sgRNA
by Golden Gate cloning (see methods) (Fig. 2B and Supple-
mentary Fig. 1B). Stbl3 bacteria were subsequently transformed
with the Golden Gate mixes in 96-deep-well blocks and grown
for »20 h at 37C (Fig. 2B and Supplementary Fig. 1C). In
order to equalize bacterial growth among wells and obtain con-
sistent plasmid yield, cultures were diluted 1:5 in fresh medium
and grown for additional 3.5 h. Analysis of bacterial growth by
spectrophotometric measurements indicated uniform cell
growth across wells (Supplementary Fig. 1D,E). Analysis of
selected plates by Sanger sequencing of isolated plasmids con-
ﬁrmed the high efﬁciency and accuracy (99%) of the cloning
procedure (Fig. 2C). Production of the entire library was com-
pleted in 10 days.
In addition to generating individual sgRNAs in an arrayed
format, we also produced two types of pooled libraries, one
containing all sgRNAs, to be used in selection screens (pooled
library), and one in which all sgRNAs targeting the same gene
were combined and maintained in a 96-well format (gene
pools, in 450 wells), to be used in high-content screens
(Fig. 2D). Both pooled libraries were generated by combining
aliquots of bacterial culture after the additional 3.5 h of growth.
All individual and pooled bacterial stocks were digitally tagged
with barcodes and stored at ¡80C (Fig. 2D).
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Assessment of sgRNA representation in the library
In order to assess the relative representation of sgRNAs in the
generated library, we performed high-throughput sequencing
of the pooled library and compared relative abundance of each
guide. Eighty-seven percent of the designed sgRNAs were
detected, showing a narrow distribution of read counts
(Fig. 2E). The raw aligned reads for the majority of sgRNA
sequences present in the pool showed less than 2-fold differ-
ence from the mean (Fig. 2E). A single outlier overrepresented
compared to the other sgRNAs was found to have contami-
nated neighboring wells in one plate (Fig. 2E). Sanger sequenc-
ing of individual plasmids isolated from re-grown glycerol
stocks allowed us to identify the contaminated wells and
replace them with the correct plasmids.
Undetected sgRNAs were re-cultured from bacterial glycerol
stocks in individual wells of 96-well blocks, and equalized to an
OD600 of »0.80 prior to plasmid extraction. Sanger sequenc-
ing indicated that 58% of the sgRNAs undetected in the pooled
library had been successfully cloned and had the correct
sequence, suggesting that they may have only been underrepre-
sented in the pooled library. Puriﬁed plasmid DNA from the
originally underrepresented wells was added to the pooled
library. The ﬁnal library comprised 94% of the designed guides
allowing targeting of all 450 target genes, with 99% of genes tar-
geted by at least 4 sgRNAs (Fig. 2F, Supplementary Table 2).
Assessment of sgRNA activity
To assess the editing efﬁcacy of the generated library, we ini-
tially selected 15 sgRNAs and examined their ability to induce
in/dels at their target sites. To do so, we transduced human
ﬁbroblasts expressing inducible Cas9 with individual constructs
and assessed in/del formation by TOPO cloning of PCR–
ampliﬁed genomic fragments of the targeted loci. Fourteen
days after Cas9 induction, 12/15 targeted sites showed in/dels,
indicating overall high editing activity (Fig. 3A). Time course
experiments indicated that in/del formation increased over
time after Cas9 induction, typically reaching a plateau at 8 days
(not shown).
To comprehensively assess the ability of individual sgRNAs
to induce in/del formation at all target genes, we generated 3
pools of 450 sgRNAs containing one sgRNA/gene each (pool 5,
pool 6, and pool 7, each one containing distinct sgRNAs for the
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Figure 1. sgRNA library design A. Basic information about the genes targeted in the sgRNA library. The number and the classes of targeted genes are indicated. B. Rela-
tive abundance of designed sgRNAs (groups 1–5) targeting all RefSeq isoforms of the corresponding genes (blue). C. Distribution of MIT speciﬁcity score across the
designed sgRNA groups 1–5. D. Distribution of targeted sites within genes, comparing newly designed sgRNAs (Henser design, blue) and sgRNA selected from the library
designed by Wang et al. [18] (Wang design, yellow). Groups 1–5 sgRNAs (Henser design) target the most 5’ exons, resulting in the formation of short truncated proteins.
In/dels induced by groups 6–7 sgRNAs (Wang design) lead to longer truncated proteins, possibly retaining partial functionality. P value: 2-way ANOVA. E. Distribution of
GC content of the target sequences across the indicated sgRNA groups. F. Predicted activity of the indicated sgRNA groups based on the Azimuth algorithm. P value: 2-
way ANOVA.
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expressing HepG2 cells with the three individual pools. Five
days after infection, genomic DNA was extracted and targeted
sites pulled-down using target-enrichment probes (see meth-
ods). Detection of in/dels by high-throughput sequencing con-
ﬁrmed high editing activity for most sgRNAs. Eighty-seven
percent of sgRNAs induced detectable in/dels and 98.6% of the
genes were targeted by at least one sgRNA (Fig. 3B,C). sgRNA
groups 6–7 showed higher activity (95% and 90% of active
sgRNAs, respectively) compared to sgRNA group 5 (79%) (P
value <0.0001 Fisher’s test), suggesting that the algorithm used
by Wang et al. to design sgRNAs may outperform the MIT
CRISPR Designer with respect to editing efﬁcacy (Fig. 3B).
However, higher sgRNA activity would not necessarily result in
higher KO efﬁciency since sgRNA groups 6–7 do not preferen-
tially target 5’ exons, unlike sgRNA groups 1–5 (Fig. 1D), and
may lead to long truncated proteins retaining partial
functionality. Thus, the combination of multiple sgRNAs
designed with different algorithms maximizes the chance of
achieving efﬁcient gene KO with our library.
Comparison between the 50 most active sgRNAs in each
sgRNA group and those showing low or undetectable activity
indicated that the number of in/dels induced by individual
sgRNAs did not correlate with abundance of the sgRNA in the
pool, GC content of the target sequence or speciﬁcity score
(Supplementary Fig. 2C). To quantify the editing activity of
each sgRNA present in the library, we calculated an observed
activity score (OAS: the number of observed in/dels normalized
to the abundance of each sgRNA in the library—see Materials
and methods) (Supplementary Table 2). The OAS showed a
signiﬁcant, albeit weak, correlation with the Azimuth RS2 score
(Kendall rank correlation coefﬁcient = 0.3, P <0.001), indicat-
ing that the algorithm is overall predictive of sgRNA activity,
Figure 2. sgRNA library generation A. Schematic representation of the vector used to generate the sgRNA library. LTR: Long Terminal Repeat; U6: U6 promoter; ccdB: sui-
cide gene; CAT/CmR: chloramphenicol resistance; BsmBI: restriction enzyme. CMV: cytomegalovirus promoter; BSD: blasticidin resistance. The lower side of the graphics
represents the ﬁnal construct containing the sgRNA (red rectangle). B. Summary of the three-step large-scale cloning protocol. C. Heatmap showing the fraction of correct
constructs in plate 1 of the library as assessed by Sanger sequencing. Only one sgRNA, indicated in white, was not successfully cloned. D. Summary of the three different
formats in which the library was generated and stored. E. Relative abundance of individual sgRNAs as assessed by next-generation sequencing of the pooled library. Each
dot represents an individual sgRNA. The red line indicates the median value of sgRNA counts. F. Number of genes with the indicated number of designed sgRNAs repre-
sented in the library. The percentage of genes targeted by at least 4 sgRNAs is indicated.
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although it returns many false positives and false negatives
(Fig. 3D, Supplementary Fig. 2C). Similar results were obtained
comparing the in/del score with the sgRNA Scorer 2.0 (Supple-
mentary Fig. 2D). Thus, while in silico analysis can help identify
active sgRNAs, actual editing efﬁcacy needs to be empirically
determined.
High sgRNA efﬁcacy was conﬁrmed at the protein level. To
perform an initial quantitative assessment of KO kinetics and
efﬁciency in polyclonal populations, we used a reporter cell line
expressing TurboRFP. FACS analysis of reporter cells transduced
with TurboRFP-targeting sgRNAs indicated rapid and efﬁcient
KO at the protein level, detecting »70% RFP-negative cells
8 days after Cas9 induction (Fig. 3E). KO of the endogenous
gene H1F0 using sgRNAs from the library showed similar results
(90% of H1.0-negative cells, as assed by immunoﬂuorescence
microscopy) (Fig. 3F). Thus, stable expression of sgRNAs allows
efﬁcient gene KO in polyclonal populations, avoiding the need
of isolating individual clonal populations of edited cells.
Sensitive detection of phenotypic effects induced by gene
knock-out in polyclonal populations
CRISPR-mediated KO offers major advantages compared to
RNAi-based approaches, allowing complete elimination of the
targeted protein. However, the low editing efﬁciency achieved
when using transiently expressed sgRNAs and the consequent
need to isolate clones limits the use of CRISPR for high-
throughput approaches. Furthermore, the inability to tempo-
rally control induction of gene KO when Cas9/sgRNA com-
plexes are transiently expressed, hinders some applications,
especially if essential genes are targeted (e.g., in vivo studies).
Using the platform that we have generated, gene KO can be
induced in polyclonal populations in a time-controlled manner,
allowing large scale generation of cell lines suitable for a variety
of in vitro and in vivo assays (Fig. 4A). To conﬁrm that the
functional consequences of gene KO are robustly detected in
polyclonal cell populations, we ﬁrst assessed whether interfer-
ence with a histone modifying protein complex led to changes
in the corresponding histone mark. To do so, we disrupted the
MSL complex, which speciﬁcally acetylates histone H4 lysine
K16 [32], by knocking-out MSL1. To maximize the KO efﬁ-
ciency we transduced cells with the pool of MSL1-targeting
sgRNAs that we generated. Upon MSL1 KO, we observed a sig-
niﬁcant reduction in the levels of H4K16Ac (P value<0.001
Student t-test), conﬁrming MSL1 loss-of-function and indicat-
ing that the molecular consequences induced by MSL1 KO
were readily detectable (Fig. 4B,C).
We then asked whether we could observe physiological con-
sequences induced by gene KO using polyclonal populations.
The gene encoding the chromatin remodeler INO80 is an
essential gene, whose loss leads to embryonic lethality and
impairs cell proliferation [33,34]. In agreement, INO80 KO
Figure 3. Validation of the sgRNA library A. Assessment of sgRNA in/del activity of the indicated guides. Assessment of activity was based on Sanger sequencing of PCR-
ampliﬁed and cloned target regions. B. Assessment of sgRNA in/del efﬁcacy of all guides included in the indicated sgRNA groups. Assessment of activity was based on
next generation sequencing of pulled-down target regions. The indicated percentage of active sgRNA is calculated based on the number of sgRNAs detected in the
infected cells. C. Percentage of genes edited by at least 1 of the 3 tested sgRNAs. D. Correlation between the observed and predicted sgRNA editing activity. Tau indicates
the Kendall rank correlation coefﬁcient (tau-b) E. FACS analysis of cells expressing TurboRFP in the presence (right) or absence (left) of TurboRFP-targeting sgRNAs. F.
Immunoﬂuorescence microscopy of uninduced (NT) or induced (DOX) cells expressing H1F0-targeting sgRNAs. Cells were analyzed 14 days after Cas9 induction. Scale
bar: 10 mm.
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inhibited cell growth and 8 days after Cas9 induction we
observed a 7-fold reduction in the number of viable cells com-
pared with the uninduced control (Fig. 4D).
Finally, to assess whether gene KO induced with our plat-
form is a suitable approach to perform in vivo functional stud-
ies, we tested the effect of INO80 KO in xenograft assays. To do
so, HRASv12-transformed ﬁbroblasts [35] expressing inducible
Cas9 and INO80-targeting sgRNAs, were injected intradermally
into immunocompromised mice. When tumors became palpa-
ble (»3 weeks after injection), doxycycline (Dox) was adminis-
tered to mice to induce Cas9 expression and gene KO in vivo.
In agreement with previous reports [34], loss of INO80 signiﬁ-
cantly inhibited tumor growth (Fig. 4E,F). As a positive control,
HRAS KO almost completely prevented tumor growth, indicat-
ing that cells escaping gene KO, which are positively selected
during tumor growth, are only a small fraction of the injected
cells and do not signiﬁcantly reduce the dynamic range of
detectable differences (Fig. 4E).
Discussion
We have generated and characterized a focused sgRNA library
targeting most human epigenetic regulators that enables com-
prehensive investigation of cellular mechanisms involving
chromatin and DNA methylation. We show overall high edit-
ing activity of the sgRNAs contained in the library and provide
a score of actual activity for 3 guides/gene to ease selection of
the most effective sgRNAs. The library can be used for a variety
of applications, ranging from loss-of-function screens to inves-
tigation of selected proteins in vitro and in vivo, visualization of
genomic loci [13] and induction of genomic rearrangements at
speciﬁc loci [10].
The library is available in three formats: a pool containing all
sgRNAs, suitable for both enrichment and drop-out selection
screens; an arrayed format in which multiple sgRNAs targeting
the same gene are combined, suitable for primary high-content
screens; an arrayed format containing individual sgRNAs,
which can be used to validate primary hits or to investigate
selected proteins in a targeted manner. Importantly, we show
that the high editing efﬁciency in polyclonal populations allows
assessment of functional consequences of gene KO without the
need of isolating clones. This removes a time-consuming step
and generates more reliable data, avoiding clonal effects that
can signiﬁcantly affect the biological interpretation of the
results, especially when heterogeneous cell populations such as
cancer cell lines are used.
Compared with alternative resources, our library offers vari-
ous advantages. First, the focused nature of the library enables
effective screening, even when complex readouts, such as clo-
nogenic or invasion assays, or microscopy-based measurements
are used. While a pooled genome-wide library requires
»200 million cells to cover its complexity 1000 times [18], only
3 million cells are enough to saturate the screen with our
focused library. Similarly, for arrayed screens, the use of our
Figure 4. Applications of the arrayed sgRNA library A. Outline of the protocol for large-scale gene editing and subsequent functional assays. B-C. Quantitative immuno-
ﬂuorescence microscopy of cells in which KO of MSL1 had been induced for 14d and control cells not expressing MSL1 sgRNAs (control). MSL1 is a member of the MSL
complex, which speciﬁcally acetylates H4K16. For quantiﬁcation, n = 218 and 123 for control and MSL1 KO, respectively. P value: Mann–Whitney test. Scale bar: 10 mm.
D. Viability assay comparing uninduced (NT) and induced (DOX) cells expressing INO80-targeting sgRNAs and inducible Cas9. n = 3. Three asterisks indicate P < 0.001
(Student t-test). E-F. Tumorigenicity assays in NSG mice comparing uninduced (NT) and induced (DOX) cells expressing INO80- or HRAS-targeting sgRNAs and inducible
Cas9. n = 4. The ﬁnal tumor volume relative to the corresponding uninduced condition is indicated in the graph. Tumors were harvested 11 weeks after injection. Two
and three asterisks indicate P < 0.05 and P < 0.001, respectively.
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library reduces the number of required plates from 383 96-well
plates [24] to 5 when using the gene pools, or to 33 when using
the individual sgRNAs. Second, the presence of 7 sgRNAs for
most targeted genes increases the conﬁdence in the results and
minimizes the rate of false-positives compared with genome-
wide arrayed libraries containing only 2 sgRNAs per gene [24],
while the design of guides with distinct strengths (targeting 5’
of the gene or optimized activity) maximizes overall efﬁcacy.
Third, being cloned into a lentiviral vector that can be easily
propagated, the generated library is a cost-effective alternative
to synthetic arrayed libraries [36]. Fourth, the ability to tempo-
rally control gene KO when combined with inducible Cas9 ena-
bles the use of sgRNAs in vivo, an important beneﬁt when using
graft models.
In conclusion, the generated CRISPR library represents a
unique resource to study epigenetic mechanisms in various
contexts, allowing both forward and reverse genetic loss-of-
function screens and targeted investigation of selected proteins
in vitro and in vivo.
Materials and methods
Cell lines
In vitro-transformed ﬁbroblasts [35] were cultured in minimal
essential media (MEM) with 15% fetal bovine serum (FBS),
HepG2 cells were cultured in MEM with 10% FBS, and HEK-
293T cells were cultured in Dulbecco’s Modiﬁed Eagle’s
Medium (DMEM) with 10% FBS. Media was supplemented
with 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml
streptomycin. To freeze cells in 96-well format, cells were
detached from the plate using 30 ml of trypsin per well. Follow-
ing addition of 70 ml of FBS containing 10% DMSO, plates
were sealed and stored at -80C for up to 4 weeks. To thaw
cells, plates were placed in a water bath at 37C for a few sec-
onds and spun for 5 min at 4C after addition of 50 ml of
medium to each well. Fresh medium (100 ml) was ﬁnally added
to each well after removal of 120 ml of freezing medium.
For generation cell lines expressing 3xFLAG-tagged induc-
ible Cas9, transformed ﬁbroblasts and HepG2 cells were trans-
duced with a lentiviral pCW-Cas9 vector [3,14]. (Addgene),
which was modiﬁed to confer resistance to hygromycin to
infected cells. Following a 7-day selection with 600 mg/mL
hygromycin, cells were plated at a very low density (200 cells/
15 cm plate) and grown for 2–3 weeks. Clones with minimal
background levels of Cas9 and responsive to induction with 1
mg/mL doxycycline were identiﬁed by both RT-qPCR of Cas9
expression and western blotting of 3xFLAG-tag (Sigma F1804).
To generate cell lines stably expressing sgRNAs, cells were
transduced with pLenti_BSD_sgRNA constructs and selected
with blasticidin (4 mg/ml) for 5 days. To induce gene KO, Cas9




Where possible, sgRNAs were designed to target the ﬁrst shared
CDS exon of identiﬁed genes (RefSeq). The most 5’ exon of
RefSeq variant 1 was utilized if it was not possible to target a
shared exon given a speciﬁc scoring threshold. For later align-
ments, the RefSeq variant 1 was used as a reference. Genomic
CDS sequences—separated into individual exons—associated
with RefSeq accessions for all gene targets were extracted using
the biomaRt package for R [37]. CDS sequences were extracted
manually from UCSC genome browser in 13 cases where the
biomaRt database could not identify the input RefSeq acces-
sion. GRCh37/hg19 (February 2009 assembly) was used as the
reference genome throughout the design stage. Five sgRNAs
per gene (Henser sgRNA groups 1–5) were evaluated for off-
target activity using the Zhang lab’s publicly available tool at
crispr.mit.edu (accessed between April and October 2015).
Guides were selected using a score threshold of at least 70
where possible, with guides scoring at least 50 used as backups.
For each gene in the library, 2 additional guides were selected
from the CRISPR library constructed by Wang et al. (Wang
sgRNA groups 6–7) [18], assuring that selected sequences did
not overlap with existing guides by at least 15 bp. The sgRNA
design by Wang et al. is based on observed activity of sgRNAs
targeting essential ribosomal genes in depletion screens. Brieﬂy,
sgRNAs with high predicted activity were designed using a sup-
port-vector-machine classiﬁer that identiﬁed up to 80 binary
features of efﬁcient guides [18]. Overall, our resulting library
contained 3150 unique sgRNA sequences with 7 sgRNAs per
target gene. A 5 0 ‘G’ nucleotide is commonly added to sgRNAs
expressed under a U6 promoter for efﬁcient RNA polymerase
III transcription; this additional step was not required in this
case as a 5 0 ‘G’ nucleotide is prepended to all protospacer
sequences automatically in the vector during cloning.
Efﬁcacy prediction
On-target efﬁcacy of sgRNAs was predicted in silico using both
Rules Set 2 (RS2) from the Azimuth project [29], and sgRNA
Scorer 2.0 (SS2) [30] prediction models using available python
scripts [RS2 v1.2 (accessed August 2016), SS2 v2 (accessed May
2017)]. In the case of RS2 only the raw sequence option (--seq)
was used in score calculations in the format of:
NNNN20merNGGNNN. The percentage of peptide remaining
following a DSB was predicted by mapping sgRNA sequences
against canonical mRNA sequences, assuming a frame-shift or
nonsense mutation would be induced at the ﬁnal nucleotide
before the PAM sequence.
Large-scale sgRNA cloning
Lentiviral vector
The lentiviral vector used to construct this sgRNA library
(pLenti_BSD_sgRNA) was generated through modiﬁcation of
the pLent_sgRNA_Lib plasmid utilized in previously published
CRISPR/Cas9 screens [31], which we obtained through Addg-
ene. The original GFP reporter was replaced with the blasticidin
resistance coding region (BSD) using GeneArt Seamless Clon-
ing and Assembly.
Library oligo synthesis and annealing
Forward and reverse oligonucleotides corresponding to the tar-
get sequences were tagged with 5 0 overhangs appropriate for
the BsmBI-based cloning strategy. Single-stranded
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complementary forward and reverse oligonucleotides were syn-
thesized at 100mM in a 96-well arrayed format by Sigma
Aldrich—resulting in 66 (2 £ 33) 96-well plates. To generate
double-stranded oligonucleotides, relevant pairs were mixed
and added to annealing buffer (10 mM Tris pH 7.5, 1 mM
EDTA, 50 mM NaCl) using the Biomek FX automated liquid
handling equipment, maintaining the 96-well arrayed format
(Supplementary Table 3). Plates of mixed oligos (x33) were
then annealed in thermocyclers by heating the reaction to 95C
for 5mins before reducing the temperature to 25C at 0.1C per
second. Following the reaction, annealed oligonucleotides were
diluted 1:200 before proceeding to Golden Gate cloning.
Cloning and transformation
Cloning of double-stranded oligonucleotides into pLenti-BSD-
sgRNA was performed using a single-step Golden Gate cloning
procedure (Supplementary Fig. 1B). Annealed and diluted oli-
gonucleotides from the previous step were added to each well
of a fresh 96-well PCR plate maintaining the original arrayed
format and combined with the cloning mix (Supplementary
Table 3). Reaction PCR plates were placed in thermocyclers
and the cloning reaction performed over the course of »2 h
using the conditions indicated in Supplementary Fig. 1. All
plates were stored at -20C until transformation.
Chemically competent E. coli Stbl3 with a transformation
efﬁciency of 1.5 £ 107 cfu/mg DNA were generated using the
Mix & Go E. coli Transformation Kit (Zymo Research). To
transform the sgRNA library, competent bacteria were thawed
and 50 ml added to each well of 96-well deep well blocks. Subse-
quently, 2 ml of constructs generated in 96-well PCR plates dur-
ing the cloning step were transformed directly into these wells.
All transformation steps were conducted on ice. CircleGrow
medium (950ml; MP Biomedicals) was added to each well, and
blocks were initially incubated overnight (ON) for »20 h at
37C. Individual glycerol stocks were generated (33 96-well
plates). All individual glycerol stocks were digitally tagged with
Data Matrix 2D barcodes for simpliﬁed tracing and stored at
-80C.
Generation of library pools
To generate the whole library pool, 200 ml of culture from wells
grown ON were transferred into the corresponding wells of
new deep-well blocks, and 800 ml of fresh medium added to
each. The new deep-well blocks were cultured for a further
3.5 h to equalize their optical density (OD) and respective plas-
mid yields (Supplementary Fig. 1D). A total of 200 ml of the
equalized culture from each well were then pooled generating
»700 ml of culture used to extract plasmid DNA. To generate
gene pools, 50 ml of equalized culture from each well corre-
sponding to the same gene were pooled together and used to
generate glycerol stocks (5 plates, 450 wells, with each well con-
taining all sgRNAs targeting the same gene).
Viral production and multiplicity of infection (MOI)
estimation
To optimize conditions for viral transduction, virus was pro-
duced in parallel in 10 cm dish- and 96-well format. For 10 cm
dish-format, lentiviral particles were produced by transfecting
HEK293T packaging cells at 80% conﬂuence with 5 mg of the
sgRNA lentiviral construct, 3.75 mg of psPax2 packaging plas-
mid, 1.25 mg of pMD2G envelope plasmid and 1 mg pAdVant-
age (Promega E1711) at a ratio of 3:1 DNA to FugeneHD
(Promega E2311). For 96-well format, the number of cells and
the amount of plasmid DNA was reduced 40 times. Approxi-
mately 24 h and 48 h after transfection, the supernatant con-
taining viral particles was recovered, ﬁltered through a 0.45 mm
ﬁlter (Millipore SLHV033RS or MSHVS4510), pooled together,
and frozen at -80oC. In order to determine the multiplicity of
infection (MOI) of the virus, 1 £ 105 ﬁbroblasts were seeded
per well of a 6-well plate and infected with serial dilutions of
virus generated in 10 cm dish-format, starting from 1:1. Follow-
ing selection with 4 mg/mL blasticidin, the number of viable
cells/well were measured and compared to a non-infected con-
trol to calculate the percentage of infected cells. The formula
P = 1-e¡m, where P is percentage of infected cells and m repre-
sents MOI, was used to determine the viral concentration yield-
ing the desired MOI in 96-well format (typically MOI = 1).
Individual sgRNA validation
Initial assessment of sgRNA activity was performed by trans-
ducing individual sgRNAs into ﬁbroblasts containing a doxycy-
cline-inducible Cas9. Cells (2 £ 106) were plated in 10 cm
dishes and infected with pLenti_BSD_sgRNA lentivirus for
24 h. Transduced cells were selected with blasticidin for 4 days,
after which Cas9 was induced for 1–2 weeks. KO was assessed
via FACS, quantitative immunoﬂuorescence microscopy, and/
or TOPO-cloning and Sanger sequencing of sgRNA target
genes. For TOPO sequencing, primers were designed to amplify
genomic DNA sequences surrounding predicted sgRNA target
sites (Supplementary Table 4). PCR was performed on genomic
DNA from cells expressing Cas9 and respective sgRNAs, and
amplicons cloned into blunt-end TOPO vectors. Resultant
TOPO-vectors were transformed into Stbl3 competent E. coli,
and DNA extracted for sequencing. Standard M13 sequencing
primers were used to sequence the cloned amplicons. For
FACS analysis a cell line transduced with empty pTRIPZ
(Open Biosystems) and expressing TurboRFP was used. FACS
analysis and immunoﬂuorescence analysis was performed as
previously described [38]. Antibodies used were anti-H1.0
(Upstate) and anti-H4K16Ac (Cell Signaling Technology).
Quantiﬁcation of ﬂuorescence intensity was performed using
Metamorph software.
Large-scale sgRNA validation
To assess the efﬁcacy on a larger scale, individual sgRNAs sepa-
rate pools were generated for sgRNA groups 5, 6, and 7, result-
ing in 3 pools, each containing a single sgRNA for each of the
450 target genes. HepG2 cells containing a doxycycline induc-
ible Cas9 were plated at 0.45 £ 106 cells/well in a 6-well plate
and were induced for 24 hours prior to infection with the above
pools in duplicate. Cells were infected with virus at MOI » 10.
24 hours after infection, cells were transferred into 60mm
dishes and selected with blasticidin for 4 days. Doxycycline was
replaced every 2 days until harvesting of genomic DNA for
sequencing 5 days post-infection.
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Next generation sequencing
To assess the representation of individual sgRNAs in the whole
library and in the pools, libraries of amplicons containing the
sgRNA sequences were generated by PCR using the Herculase II
polymerase kit (Agilent). Brieﬂy, 150 ng of the pooled plasmid
libraries were used to generate 268 bp-long amplicons, which
included the sgRNA sequence and the P5 and P7 adaptors for
Illumina sequencing. All primers were annealed at a temperature
of 60C for 30 seconds and the reaction performed for 30 cycles.
All reactions were performed in technical triplicates and their
products pooled and run on a 2% agarose gel to conﬁrm a single
band of 268 bp. The bands were subsequently cut from the gels
and puriﬁed using the gel puriﬁcation Kit (Qiagen) as per manu-
facturer’s protocol. Puriﬁed products were sequenced with a
HiSeq2500 using custom sequencing and indexing primers
(SeqP and IndexP, Supplementary Table 4). Following sample
demultiplexing, all sgRNA sequences were trimmed and aligned
to the target sequences to assess sgRNA representation (normal-
ized read count). To detect in/dels at targeted regions, libraries
were generated using the SureSelect Target enrichment kit (Agi-
lent) using custom probes and following the manufacturer’s
instructions. Probes were designed to cover 2 kb regions cen-
tered on each target site. When multiple target sites were located
in the same exon, the 2 kb region was centered on the exon mid-
dle point. Probe tiling parameters were: Tiling density: 1x; Mask-
ing: Least Stringent; Boosting: Maximize Performance.
Large-scale in/del analysis
The quality of the sequenced reads was assured using FastQC
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/).
Alignment was carried out against the UCSC hg19/GRCh37
genome assembly, using BBMap (v. 36.59) (http://jgi.doe.gov/
data-and-tools/bbtools/bb-tools-user-guide/bbmap-guide/), a
global aligner that is able to align longer in/dels. A two-stage
alignment strategy was used to robustly identify reads that con-
tained in/dels. In the ﬁrst phase, reads were aligned to the
genome disallowing any reads that contained in/dels. In this
phase, reads that aligned in a proper pair (unedited or correctly
repaired sequences) were discarded and the remainder was
taken forward. In the second phase, the remaining reads were
aligned to the genome, allowing in/dels up to 2000 bp. Dupli-
cates were marked using Picard (v. 2.1.0). Reads that were
marked as duplicates, or that had a mapping quality score of
less than 38 were ﬁltered using samtools (v. 1.2) [39] and sam-
bamba (v. 0.6.0) [40]. This two-phase approach was necessary
to discriminate between background noise and signal in our
dataset since infection with pooled sgRNAs returned a high
proportion of unedited sequences for each target sequence
(only a small fraction of cells was transduced with each
sgRNA). All subsequent downstream analysis of the reads was
performed in R (v. 3.3.2). The location and size of in/dels in
reads were identiﬁed from the CIGAR string. In/dels were only
considered valid if they occurred within 2 nucleotides of the
Cas9 cleavage site (deﬁned as 6 nucleotides upstream of the
end of the guide RNA including the PAM sequence). Any in/
dels that could also be detected in the untransduced HepG2
sample were removed from the analysis. To calculate the
‘observed activity score’ (OAS), the number of in/dels observed
for each sgRNA was normalized to its representation in the
pools: the mean number of observed in/dels across two biologi-
cal replicates (mID) was divided by the normalized read count
for that sgRNA [raw reads for a single sgRNA (sgR) divided by
total reads of all sgRNAs in the pool (TR)  100].
OAS ¼ mID
sgR TRð Þ100
Viability and tumorigenicity assays
To assess the functional consequences of CRISPR-mediated KO
induced by sgRNAs in our library, transformed human ﬁbro-
blasts expressing inducible Cas9 were transduced with sgRNAs
against either INO80 (a pool of 7 sgRNAs) or HRAS (1 sgRNA).
Following selection of infected cells with blasticidin, the resulting
polyclonal populations were used for phenotypic validation. For
viability assays, cells transduced with INO80-targeting sgRNAs
were seeded in triplicates at 100,000 cells/well in a 6-well plate
and cultured in the presence or absence of doxycycline (1 mg/
mL) for 8 days. The ﬁnal number of cells/well was determined
by manual cell counting in the presence of Trypan Blue to dis-
card dead cells. For functional in vivo assays, 5 £ 105 trans-
formed ﬁbroblasts transduced with INO80-targeting sgRNAs
and expressing inducible Cas9 were injected intradermally
together with 1 £ 105 carrier hTERT-immortalized ﬁbroblasts
in 50 ml of PBS into both ﬂanks of 6–8 week old male NOD/
SCID/Interleukin 2 receptor g null (NSG) mice. After 3 weeks,
when tumors became palpable, mice were randomly grouped
and administered either 2 mg/mL dox in 1% sucrose water or
1% sucrose alone. Six weeks after treatment, tumor volume was
measured according to the formula d2D/2, where d and D are
the shortest and the longest diameter of each tumor, respectively.
Cells expressing HRAS-targeting sgRNAs were used as a control.
Animal studies were conducted in accordance with the Crick
project license PPL 70/8167 approved by the Home Ofﬁce.
Statistical analyses
All data visualization and statistical analyses were conducted
using the ggplot2 and stats packages for R, or MS Excel. The
test used for each analysis is indicated in the ﬁgure legend.
Data availability
The datasets generated during and/or analyzed during the cur-
rent study are available from the corresponding author on rea-
sonable request
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